Copyright
©The Author(s) 2024.
World J Hepatol. Apr 27, 2024; 16(4): 650-660
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.650
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.650
Inclusion criteria | Exclusion criteria |
Involve human solid organ transplant recipients | Presents risk data on only one of the immunosuppressant medications |
Independent malignancy risk analysis related to both immunosuppressants mycophenolic acid and tacrolimus | Does not specify type of immunosuppression |
Contains a group of participants exposed to tacrolimus or mycophenolic acid, exclusive of the other | Mean follow up less than one year (given the slow growing nature of malignancy) |
Greater than 100 participants | Not published in English |
Greater than 5 cases of malignancy | Full text not available |
Randomised controlled trials and observational studies | Systematic reviews and meta-analyses |
- Citation: Liu D, Youssef MM, Grace JA, Sinclair M. Relative carcinogenicity of tacrolimus vs mycophenolate after solid organ transplantation and its implications for liver transplant care. World J Hepatol 2024; 16(4): 650-660
- URL: https://www.wjgnet.com/1948-5182/full/v16/i4/650.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i4.650